摘要
为了检测初治急性髓系白血病(AML)细胞CD34+抗原的表达,并分析其与预后的关系,应用间接免疫荧光法检测了238例AML患者。结果表明:238例AML中CD34阳性表达者有92例,占38.7%。除M3无CD34阳性表达外,CD34+表达与FAB亚型M0、M1有关;CD34+组完全缓解率为32%,明显低于CD34-组的61%;除淋系抗原CD7在CD34+组表达明显增高外,其它淋系抗原表达在两组间无差异(P<0.05)。结论:有CD34+表达的AML患者预后差、CR率低,检测CD34表达对判断AML疗效有一定价值。
To explore CD34^＋ antigen expression in new diagnosed acute myeloid leukemia （AML） and analyze the prognosis for CD34^＋ AML patients, the expression of antigen CD34 in 238 AML patients was detected by indirect immunofluorescence assay. The results showed that CD34 in 92 out of the 238 patients （38.7%） were positive, there was relationship between the CD34^＋ expression and FAB subtypes （ M0, Ml ）, and no CD34^＋ expression was observed in M3 subtyes. The complete remission rate of CD34^＋ AML patients was 32%, which was lower than that of CD34^- AML（61% ）. The lymphoid-associated antigen （CD7） was significantly increased in CD34^＋ AML patients, compared with CD34 - patients （P 〈 0.05 ）. It is concluded that CD34^＋ AML patients show poor prognosis and lower CR rate. The detection of CD34 expression is of some value in predicting prognosis in AML.
出处
《中国实验血液学杂志》
CAS
CSCD
2005年第5期812-814,共3页
Journal of Experimental Hematology
基金
新疆维吾尔自治区科技厅自然科学基金资助
编号200121102
